Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting by Sharma, Rakesh K et al.
© 2009 Sharma et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 965–972
Vascular Health and Risk Management
965
R e V i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Aspirin and clopidogrel hyporesponsiveness  
and nonresponsiveness in patients with coronary 
artery stenting
Rakesh K Sharma1 
Hanumanth K Reddy1 
Vibhuti N Singh2 
Rohit Sharma1 
Donald J  Voelker1 
Girish Bhatt1
1Medical Center of South Arkansas, 
el Dorado, University of Arkansas 
for Medical Sciences, Little Rock, 
AR, USA; 2Bayfront Medical Center, 
St. Petersburg, University of South 
Florida, Tampa, FL, USA
Correspondence: Rakesh K Sharma 
The Heart and Vascular institute of South 
Arkansas, 700 west Grove St, el Dorado, 
AR-1730, USA 
email rk1965@gmail.com; rsharma@
uams.edu
Abstract: Patients undergoing coronary artery stenting receive an antiplatelet regimen to 
reduce the risk of antithrombotic complications. Current guidelines recommend the use of acetyl 
salicylic acid (aspirin) and clopidogrel as evidenced by large clinical trials. There has been a 
concern about variable responses of patients to aspirin and clopidogrel which may predispose 
them to subacute stent thrombosis or late stent thrombosis. Up to 25% of patients with acute 
myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) were found 
to have hyporesponsiveness or resistance to clopidogrel which may predispose them to recurrent 
events. Dual antiplatelet regimen is a standard therapy in these patients and there is always a 
concern about variable responses to aspirin and clopidogrel predisposing them to acute coronary 
syndrome (ACS). Prevalence of this hyporesponsiveness or resistance may be due to noncompli-
ance, genetic mutations, co-morbid situations and concomitant use of other drugs. This issue 
is of considerable importance in the era of coronary drug eluting stents when a long-term dual 
antiplatelet regimen is needed. This paper is a review for clinicians taking care of such patients 
with hyporesponsiveness or nonresponsiveness to dual antiplatelet regimen.
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Background
Do we manage hypertension without monitoring blood pressure? Do we manage 
diabetes mellitus (DM) without monitoring glucose? Do we manage warfarin sodium 
(Coumadin®) without monitoring international normalized ratio (INR)? If so, why do 
we use an antiplatelet regimen without monitoring platelet function testing. It is not 
uncommon for patients with recent coronary intervention with bare metal stents (BMS) 
or drug eluting stents (DES) to present to the emergency department with chest pain. 
Just as we monitor DM with a gluco-meter or warfarin with INR, we should monitor 
antiplatelet regimens in patients with coronary artery stenting. It is crucial to understand 
the heterogeneous response of patients to aspirin and clopidogrel which can result in 
unstable angina, or myocardial infarction (MI).1 Trials are ongoing (Gauging Respon-
siveness with a VerifyNow Assay-Impact on Thrombosis And Safety2 [GRAVITAS] 
and the ARCTIC study3) to determine whether tailored antiplatelet therapy, using 
platelet function testing, reduces major adverse cardiovascular events after DES.
Dual antiplatelet regimen with aspirin and clopidogrel has been shown to signifi-
cantly reduce the cardiovascular events.4 Although clopidogrel mostly reduces risk 
of cardiovascular events after coronary stenting, a significant number of events still 
occur in these patients.1 These events may be due to subtherapeutic responses of some 
patients to aspirin and clopidogrel, predisposing them to subacute stent thrombosis or Vascular Health and Risk Management 2009:5 966
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late stent thrombosis. Up to 25% of patients with acute MI 
(AMI) undergoing percutaneous coronary intervention (PCI) 
were found to have variable response to clopidogrel, predis-
posing them to recurrent events of acute coronary syndrome 
(ACS).1 Prevalence of this hyporesponsiveness or resistance 
may vary in certain co-morbid situations as described below. 
This is a critical issue in the era of DES with need of long-
term dual antiplatelet regimens.
Variable responses to antiplatelet 
agents and their mechanism
The exact definition of “resistance” to antiplatelet therapy on 
the basis of physiology does not exist. However, there is a 
significant prevalence of variable response to dual antiplatelet 
regimens similar to different responses to anti-hypertensive 
therapy or warfarin therapy. Therefore, it is imperative to 
understand this variable response or hyporesponsiveness to 
aspirin and clopidogrel in these patients. A clear definition 
of this response should be established and, based on this, one 
may be able to categorize patients as a responders, hypore-
sponders, nonresponders, or resistant and thus manage their 
therapeutic regimen accordingly.
The effect of aspirin is mediated by the irreversible 
inactivation of cyclo-oxygenase (COX-1), leading to the 
prevention of thormboxane A2 generation from arachidonic 
acid.5 Following oral administration, aspirin is effective as 
an antiplatelet agent within 60 minutes. COX-1 is rapidly 
resynthesized by nucleated cells, such as endothelial cells, 
and therefore the effect of aspirin on nucleated cells lasts 
only for a relatively short time. In contrast, the effect of 
aspirin on platelets (anucleate cells) lasts for the life of 
platelets (7–10 days). Thienopyridines inhibit platelets via a 
blockade of P2Y12 adenosine diphosphate (ADP) receptors.6 
As the mechanisms of aspirin and thienopyridines are 
complementary, the combination of both drugs has a greater 
degree of inhibition of platelet aggregation than either one 
alone. Clopidogrel is a pro-drug and is activated through 
sequential oxidative steps in the liver. After absorption, 85% 
of drug is inactivated by esterases (hydrolase enzyme) and 
only 15% remains for activation by the liver to its active 
metabolite through several cytochrome 450 (CYP-450) 
proteins. Therefore, genetic mutation or polymorphism of 
such subenzymes can affect the therapeutic response of 
clopidogrel.7–9
Based on this genetic polymorphism, by means of a 
simple buccal swab or blood sample, 3 phenotypes can be 
identified as being a: poor metabolizer (PM); intermediate 
metabolizer (IM), or normal metabolizer (NM). Underlying 
genetic mutation is due to variation in alleles (nucleotide 
sequences). The laboratory testing for this CYP-450 2C19 
DNA mutation is done by identifying 8 different kinds 
of alleles. The nomenclature of this CYP 2C19 mutation 
is reported as *1 (star 1) to *8 (star 8).10 The presence of 
CYP 2C 19 *2 allele is associated with reduced clopido-
grel responsiveness and this is related to increased risk 
of MI, stent thrombosis. The frequency of this mutation in 
Caucasians and African Americans is 30%.8 A poor metabo-
lizer, as diagnosed by genetic testing, may exhibit different 
responsiveness to clopidogrel due to a failure to generate 
sufficient active form metabolites, which then leads to a lack 
of therapeutic effect. In a recent study, 162 healthy subjects 
were treated with clopidogrel and approximately 30% of 
these were found to have at least one CYP2C19 reduced-
function allele that led to a relative reduction of 32.4% of 
the active metabolite of clopidogrel in plasma.8 Moreover, 
among subjects treated with clopidogrel in TRITON-TIMI 
38, carriers of the *2 defective gene (CYP2C19 reducing 
function allele called *2 genotype) had a relative increase of 
53% in the composite primary efficacy outcome of the risk of 
death from cardiovascular causes, MI, or stroke compared to 
noncarriers.11 This may lead to the need for unconventional 
doses of clopidogrel or an alternative oral antiplatelet drug in 
such patients. CYP2C19 metabolizing enzyme also catalyzes 
the biotransformation of many other drugs12 and the concomi-
tant use of such drugs with clopidogrel may also change the 
efficacy of antiplatelet therapy. Various biological factors 
such as genetic polymorphism or gene mutation may account 
for such hyporesponsiveness or nonresponsiveness. Other 
causes of hyporesponsiveness of antiplatelet drugs may be 
as simple as noncompliance13–16 or poor absorption,17 due to 
abnormalities in the mechanism of action or genetic makeup.18 
Smoking has also been proposed to cause hyporesponsiveness 
in both aspirin and clopidogrel patients,1,16,19 whereas other 
researchers have reported that smokers were likely to be 
Table 1 Mechanisms of “resistance” to aspirin and clopidogrel
Non compliance
Poor absorption
Sub optimal dose
Smoking
Genetic polymorphism
Thrombocytosis
Concomitant medication
Co-morbid conditions
Severe coronary artery diseaseVascular Health and Risk Management 2009:5 967
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responders.1 Gremmel and associates reported that cigarette 
smoking was associated with enhanced efficacy of clopido-
grel but not aspirin, on platelet inhibition in vitro testing.20 
Bliden et al have also shown that current smokers prescribed 
clopidogrel showed lower platelet aggregation.21
Methodologies for the evaluation 
of platelet function
There are many different types of platelet function tests, 
which vary in methodological complexity. Different methods 
of evaluating platelet function revolve around the measure-
ment of platelet aggregation, platelet reactivity, platelet 
receptor expression, measurement of platelet-released factors 
on activation, and intracellular platelet signaling. Although 
there is no standard definition of hyporesponsiveness or 
nonresponsiveness or resistance to antiplatelet drugs, it is 
important to identify the patients with these conditions. 
In the published literature, definitions of aspirin resistance or 
clopidogrel resistance depend upon the different methodolo-
gies used in studies (Table 2). A brief description of the most 
commonly used tests to evaluate the efficacy of antiplatelet 
drugs are described as follows.
PFA-100 system
The PFA-100 system simulates high shear platelet function 
within the test cartridges.22 It is a simple, rapid test and only a 
small sample of blood is required. PFA-100 tests use agonists 
such as epinephrine or ADP to mimic high shear stress on 
platelets. This test reports the platelet function as “closure 
time” (CT), which is the time platelets take to occlude an 
aperture in the membrane coated with collagen/epinephrine 
(C/EPI) or collagen/ADP (C/ADP). Because clopidogrel 
does not affect CT with C/EPI, the C/ADP test is used for 
clopidogrel efficacy.23 This test has not been shown to have 
significant correlation with other assays like light transmit-
tance aggregometry (LTA), vasodilator-stimulated phospho-
protein (VASP) or VerifyNow®.15,24
Platelet-platelet aggregation testing
Aggregation is the most common measure of platelet reac-
tivity and platelet inhibition. This assay is based on platelet 
aggregation by stimulation with various agonists. Such 
aggregation testing between pretreatment and post-treatment 
of aspirin or clopidogrel are the most common estimates of 
responsiveness to aspirin or a P2Y12 receptor inhibitor like 
clopidogrel.25 Historically, the “gold standard” test is LTA.17 
LTA uses an optical device that measures the rate and extent 
of change in light transmittance caused by platelets aggregat-
ing in a whole blood sample. This test determines the level of 
platelet function in response to a variety of agonists, as there 
are many pathways through which antiplatelet medications 
work. Blood samples with inhibited platelets (with antiplate-
let medication) will produce low levels of light transmittance 
compared to normal functioning platelets which aggregate 
normally. This test has been widely used to measure the effect 
of dual antiplatelet regimens. LTA testing is tedious, time 
consuming and requires specialized staff, compared to rapid 
point-of-care (POC) assays, which are simple, less laborious 
and time efficient. VerifyNow® is one of the POC platelet 
aggregation tests that does not require sample preparation 
or pipetting and is also strongly correlated with LTA.26,24 
By this methodology, aspirin response is reported as aspirin 
reaction units (ARU). Aspirin blocks platelet activation by 
preventing COX-1 enzyme from converting arachidonic acid 
to thormboxane A2. The extent of this blockade is determined 
as ARUs. More than 550 ARUs is considered as diminished 
aspirin-induced platelet dysfunction.27–30 Thienopyridines, 
like clopidogrel, block platelet activation via P2Y12 ADP 
receptors and the extent of this blockade is reported as P2Y12 
reaction units (PRU). This test takes advantage of differ-
ent receptors of platelets stimulated by different agonists. 
Thrombin receptors are strong platelet activators and func-
tion independently of P2Y12 ADP receptors. The base value 
(base PRU) is calculated by stimulating these receptors to 
estimate the total possible platelet aggregation irrespective 
Table 2 Definition of aspirin and clopidogrel hyporesponsiveness, nonresponsiveness or “resistance”
Aspirin Clopidogrela
Reference Responders Hyporesponder Resistant Reference
ARU  550 (lack of ASA-induced platelet dysfunction) 39 30% 10%–29% 10% 28
C/ePi-CT  193 seconds 14 40% 40% 27
C/ADP-CT  121 seconds 13 30% 10%–30% 10% 29
10% 10% 30
aResponse (%) of platelet inhibition by clopidogrel.
Abbreviations: ARU, aspirin reaction units; C/ePi-CT, collagen/epinephrine closure time; C/ADP-CT, collagen/ADP closure time; ASA, aspirin.Vascular Health and Risk Management 2009:5 968
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of the patient taking or not taking clopidogrel. Then the 
extent of platelet inhibition by clopidogrel can be measured 
by using a selective ADP agonist to measure P2Y12 ADP 
receptor inhibition. The percentage inhibition of P2Y12 
ADP receptors is determined by the difference between base 
PRU and PRU determined from ADP agonist (as illustrated 
in Figure 1). Less than 20% inhibition indicates low to no 
clopidogrel-induced inhibition of platelet function.
VASP phosphorylation
The surface expression of platelets can be determined by flow 
cytometery. Using monoclonal antibodies, platelet function can 
be determined by exploiting the different receptor expression 
of resting and activated platelets.17 This test (VASP) exploits 
the mechanism of intracellular signaling;24,31 the advantage 
of VASP phosphorylation testing is its specificity for the 
P2Y12 signaling pathway, although drawbacks include sample 
preparation, the need for experienced staff, and the expenses 
of the process.
Tests dependent on factors released  
from activated platelets
Some tests measure the factors released by activated 
platelets as a measure of platelet activation such as serum 
or thormboxane B2 and urinary 11-dehydro-thromboxane 
B2.17 These are COX-dependent and nonspecific. Moreover, 
urinary 11-dehydro-thromboxane depends on renal function. 
Another test, platelet-derived-miroparticles is expensive, and 
requires sample preparation and flow cytometery.26
Factors causing hyporesponsiveness 
or nonresponsiveness
A major concern after interventional procedures is an 
ischemic event, often caused by activated platelets at the 
site of a coronary stent implantation, which underscores 
the critical role of antiplatelet agents in PCI. Most of the 
time, the assumption is that dual antiplatelet regimens are 
efficacious without any objective testing. Unfortunately, not 
all patients respond equally and up to one-third of patients 
on an antiplatelet regimen do not experience the expected 
results.26 It is very important to identify these nonresponders, 
especially with the increasing use of DES. Nonresponders 
are at 5 times greater risk of MI, stent thrombosis and death 
than responders.32,33 Numerous factors may contribute to this 
unresponsiveness which may include noncompliance, drug 
interactions, DM, chronic renal failure or genetic makeup.
Factors modifying the efficacy 
of aspirin
Recent observations suggest that the primary cause for 
aspirin resistance may be poor compliance.34,35 Hence, it is 
imperative to ensure compliance with an aspirin regimen 
prior to platelet function testing. Another important factor 
leading to aspirin resistance may be concomitant use of 
Aspirin blocks platelet
activation by preventing
COX-1 enzyme by preventing
conversion of arachidonic
acid to thromboxane A2
ARU: represents extent 
of this blockade
Thrombin receptors activate 
platelets independently of P2Y12 
The BASE result is detemined by 
stimulating these receptors to
estimate total possible platelet
aggregation while patient is on
clopidogrel
% inhibition is determined 
by the % difference 
between PRU and BASE 
Thienopyridines block platelet
activation via P2Y12 ADP receptor
PRU value is determined from the 
extent of this blockade
Figure 1 Understanding platelet function testing.
Abbreviations:      AA, arachidonic acid;   PRU, P2Y12 reaction units;    ARU, aspirin reaction units;   TXA2, thromboxane A2.Vascular Health and Risk Management 2009:5 969
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nonsteroidal anti-inflammatory drugs such as ibuprofen, 
which interferes with COX-1 acetylation. Even though some 
investigators have suggested increasing the aspirin dose in 
such patients, in vitro studies have shown that increasing 
the dose of aspirin may not affect COX-1 inhibition36 and 
may work through a non-COX-1 inhibition pathway. Aspirin 
resistance or hyporesponsiveness may be also due to age or 
gender issues. Many studies have shown that women are 
more likely to have aspirin resistance and the majority of 
these subjects are postmenopausal.16,37 However, this has 
been disputed in other studies.38 Some studies have shown 
that advanced age may be an important factor39 and may be 
due to decreased metabolism of aspirin in old age. Therefore, 
it is important to test the antiplatelet efficacy of aspirin in 
patients with PCI.
Furthermore, this may help determine if baby aspirin is 
useful in such patients. Certain co-morbid conditions such 
as DM and chronic renal failure may cause hyporesponsive-
ness to aspirin.14,39,40 Some studies found a higher prevalence 
of nonresponders in smokers while other researchers have 
disputed this.41
Factors modifying the efficacy 
of clopidogrel
The most important cause of variable platelet activity 
suppression may be noncompliance and inadequate dosing. 
Resistance to clopidogrel may co-exist with aspirin and this 
may be prevalent up to 50% of patients with aspirin resistance40 
(or it may present by itself). Subacute thrombosis of coronary 
stents in the CREST study was found to be more common in 
patients with hyporesponsiveness to clopidogrel.42 Clopido-
grel is a pro-drug and its active metabolite irreversibly inhibits 
the binding of P2Y12 ADP receptor on platelets.43 Such 
metabolism invokes the possibility of the concurrent use of 
other medications as contributing factors to hyporesponsive-
ness in patients with coronary artery stenting. Concomitant 
use of other drugs, such as calcium channel blockers (CCB), 
angiotensin-converting enzyme (ACE) inhibitors, or beta 
blockers, does not cause hyporesponsiveness to clopidogrel, 
although a higher number of nonresponders is seen with 
concomitant use of CCB and ACE inhibitors.30 A recent study 
by Siller-Matula et al showed that coadministration of CCB 
decreased platelet inhibition44 though in vitro incubation 
with CCB did not alter platelet aggregation in patients taking 
clopidogrel. This finding suggests that the negative effect in 
vivo may be at the level of metabolic pathways.
There has been much concern about the use of proton 
pump inhibitors (PPI) in conjunction with clopidogrel. 
A recent retrospective review of 8205 patients published 
in JAMA showed a strong association of adverse clinical 
outcomes when clopidogrel was used in conjunction with 
omeprazole,45 though this was recently disputed in a late 
breaking trial (COGENT) at the TCT Conference on 
September 24, 2009 in San Francisco, USA (http://www.
tctmd.com/Show.aspx?id=85972). Omeprazole (Losec® or 
Prilosec®) is both a substrate and an inhibitor of CYP 2C19 
and it may decrease the metabolism of clopidogrel to its 
active metabolite. Other PPIs that are CYP2c19 inhibitors 
are esomeprazole (Nexium®), lansoprazole (Prevacid®) and 
rabeprazole (Aciphex®). A recent clopidogrel medical out-
come study has also suggested a similar interaction between 
PPI and clopidogrel.46
Management strategies
A standard definition of hyporesponsiveness or nonre-
sponsiveness or resistance does not exist. One may also 
argue that incidence of resistance or hyporesponsiveness 
is overestimated. But there are several studies showing that 
a poor response to these drugs may translate into adverse 
outcomes as discussed earlier. Increasing the dose of aspirin 
has been shown to improve the response in some patients.39 
The impact of increased clopidogrel dosing was evaluated 
in patients with suboptimal response to clopidogrel in the 
OPTIMUS trial.47 This study showed that a dose of 150 mg 
of clopidogrel significantly decreased the platelet aggrega-
tion compared to a 75 mg dose. Likewise, Gurbel et al48,49 
showed better efficacy of 600 mg compared with 300 mg 
loading dose. Furthermore, the combination of clopidogrel 
with a synergistic antiplatelet agent like dipyridamole can 
also improve the response.50 Theoretically cytochrome P 450 
inducers can increase the active metabolites of clopidogrel, 
which could be an alternative to an increased dose, especially 
if there is gastrointestinal intolerance to the drug.
New drugs on the horizon
Other drugs on the horizon include a new thienopyridines 
agent (prasugrel) which has been evaluated in several large 
scale trials.51,52 In these studies, a loading dose of 60 mg 
and maintenance dose of 10 mg of prasugrel produced 
more consistent platelet inhibition compared to clopido-
grel with a loading of 300 mg and maintenance of 75 mg. 
This translated into a lower rate of combined primary out-
comes of death, nonfatal MI and stroke in high-risk patients 
with ACS. Prasugrel also demonstrated a 50% reduction in 
stent thrombosis in one trial.11 However, superior efficacy of Vascular Health and Risk Management 2009:5 970
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this agent has been somewhat offset by the increased risk of 
bleeding. While this drug has been approved in Europe for 
some time, the Federal Drug Administration (FDA) approval 
of this antiplatelet drug on July 10, 2009 was a major step 
forward in patients with ACS and PCI in the US. This may 
also be helpful in patients with CYP2C19 mutation, as it may 
not affect the pharmacokinetics and pharmacodynamics of 
prasugrel compared to clopidogrel.
Another highly selective, oral, nonthienopyridine drug is 
ticagrelor (AZD6140) which has been investigated in a large 
phase III trial.53,54 This also works by antagonizing ADP at 
the P2Y12 receptors; it does not require transformation to 
active metabolite and has a half-life of 7 to 8 hours.55 The 
safety and efficacy of ticagrelor were investigated in a trial 
named PLATO (Platelet Inhibition and Patient Outcome), 
the results of which were presented at European Society 
of Cardiology (ESC 2009) and simultaneously published 
in N Engl J Med.56 In this study patients were randomized 
for a double blind trial to a Ticagrelor group (9333 patients 
with loading dose of 180 mg followed by 90 mg twice daily) 
or a clopidogrel group (9291 patients with loading dose 
300 mg followed by 75 mg daily).56 Death from vascular 
causes, MI or stroke within 12 months occurred less 
frequently in the ticagrelor group. The potential availability 
of 3 ADP receptor P2Y12 inhibitors may make it possible 
to individualize antiplatelet regimens rather than a “one size 
fits all strategy”. Ticagrelor may be preferred in acute ACS 
patients with unknown anatomy, in whom coronary artery 
bypass grafting may be anticipated, as this is a reversible ADP 
receptor inhibitor. There may be a potential for switching 
clopidogrel or prasugrel to ticagrelor in patients who need 
elective surgery. This may become the antiplatelet agent of 
choice in situations where surgical procedures cannot be 
deferred.55 Other new classes of antiplatelet agents include 
thrombin receptor antagonists called protease-activated 
receptor (PAR-1) inhibitors.57,58 PAR-1 is the main platelet 
receptor for thrombin, the inhibition of which may lead to 
the development of novel antiplatelet agents.
Conclusions
Platelets display an enormous complexity by their variety 
of receptors and the myriad of molecules they secrete. 
These receptors and molecules mediate a large number of 
physiologic and pathophysiologic processes and hence are 
a target for multiple antiplatelet agents. Variable responses 
to oral antiplatelet regimens are well known. Therefore, 
it is important to distinguish between hyporesponsiveness or 
nonresponsiveness or resistance (failure to inhibit platelets 
activity), and treatment failure (the clinical outcome of a 
recurrence of ischemic events). As described earlier, the 
prevalence of hyporesponsiveness or nonresponsiveness 
or resistance may be an aberration of the methodology; 
however, there is clearly accumulating evidence that in vivo 
resistance to oral antiplatelet regimens leads to a higher 
risk of atherothrombotic complications such as unstable 
angina, and MI. New developments in drugs may offer a 
narrow range of response variability leading to more predic-
tive efficacy. Antiplatelet testing or genotyping may help 
uncover the underlying mechanisms of hyporesponsiveness 
or nonresponsiveness or resistance and help the develop-
ment of personalized patient oral antiplatelet regimens. 
There is a need for large-scale studies documenting the 
efficacy of point of care assessment of platelet function, 
which will be a true departure from the “one size fits all” 
strategy in managing antiplatelet regimens in coronary 
artery stenting.
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